Life Sciences + Healthcare, Germany, United Kingdom, and Brussels
LONDON, March 12, 2008– Lawyers from the London office of Morrison & Foerster MNP have advised BHK Inc. (‘BHK’) on its introduction to AIM.
BHK – the first Korean company to list on AIM – is a developer and manufacturer of medical and digital technology with three divisions specialising in cell therapy, artificial organs and advanced consumer electronics. BHK is listed on the Korea Exchange and has a market capitalisation of approximately $80 million.
On AIM, BHK has a GDR (Global Depository Receipt) which commenced trading at an opening price of 84.5 pence (each GDR represents 1 Ordinary Share). Jong Weon Choi, Chairman and CEO of BHK, said: “It is a pleasure to announce BHK’s successful admission to AIM. This is an important part of our growth strategy, as an additional London listing will enhance our reputation in key markets and provide greater access to new capital.”
The Morrison & Foerster team was led by corporate partner Ed Lukins, supported by London associates Georgie Shmuel, Mark O’Donnell and Kristian Shearsby. London based US qualified associate Stephanie Wingader gave advice on US securities law issues. Ed Lukins said: “We were delighted to advise BHK on its trailblazing entry into the London AIM market. This assignment highlights the firm’s strong links with the Far East business community and exemplifies two key strengths of the London office; our deep understanding of global technology and life sciences sectors and our UK financing capabilities.”
©1996-2019 Morrison & Foerster LLP. All rights reserved.